Navigation Links
Growth Achieved in Spherix's Health Sciences Consulting Business
Date:11/29/2007

Phase 3 Clinical Trial on Track, Market Research Contracts Signed

BELTSVILLE, Md., Nov. 29 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX) has recently signed contracts to provide technical and regulatory consulting services to several major consumer, food, ingredient, and pharmaceutical companies. Spherix's Health Sciences Consulting Division provides scientific and strategic support for suppliers, manufacturers, distributors, and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides.

"I am very pleased with the progress made in our Health Sciences Division," said Claire Kruger, CEO and Director of Health Sciences of Spherix. "Revenues earned through these efforts will add to our substantial cash reserve, and will be very useful moving forward."

The Company further reported that its Phase 3 clinical trial of Naturlose(R) as a treatment for Type 2 diabetes is progressing on schedule. Since moving the entire study to the United States, patient recruitment has increased and, logistically, everything is moving ahead much more efficiently. The protocol for the Company's dose ranging study has been finalized and is scheduled to begin later this year. An additional study to determine if Naturlose will work with only one dose per day is being finalized, and it is hoped that this study will begin early next year. Results from a recent trial evaluating efficacy of tagatose in toothpaste that was conducted at the University of Maryland did not show significant activity; further trials for this endpo
'/>"/>

SOURCE Spherix Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Diabetes Research Institute Invention Promotes Growth of Stem Cells into Insulin-Producing Cells
2. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
3. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
4. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
5. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
8. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
9. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
10. Tone Deafness Explained, from the Harvard Health Letter
11. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... July 24, 2014   Royal Philips (NYSE: ... it has received 510(k) clearance from the U.S. Food ... ultrasound system, VISIQ, in the U.S. VISIQ ... benefits of greater mobility, performance and simplicity into a ... diagnostic scans for more OB patients. This ...
(Date:7/24/2014)... Texas , July 24, 2014  To ... the cardiovascular market that could impact patient care ... Spring 2014 CV Watch , "Innovations in Cardiovascular ... provides hospitals with guidance and details on promising ... patient needs and understand how these options impact ...
(Date:7/24/2014)... Second Quarter and Recent Highlights: , ... effective September 2, 2014 , Product revenues grew ... ® revenues grew 14 percent year-over-year to $15.3 ... percent year-over-year to $1.1 million , HeRO ® ... million , Tissue processing revenues decreased 6 percent ...
Breaking Medicine Technology:Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 2New Novation CV Watch Shows Recent Technology Innovations Could Drive Cardiovascular Product Costs Up by as Much as 35 Percent 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 2CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 3CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 4CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 5CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 6CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 7CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 8CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 9CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 10CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 11CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 12CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 13CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 14CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 15CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 16CryoLife Second Quarter 2014 Revenues Increase 3 Percent to a Record $34.7 Million 17
... , WASHINGTON, Dec. 18 John Kopchinski, ... successful, record-setting "qui tam" case against Pfizer Inc. , ... ethics for 2009. , Ethisphere, a think tank that ... compiles an annual list of the 100 most influential ...
... , INDIANAPOLIS, Dec. 18 Eli Lilly and Company (NYSE: ... vice president and chief financial officer for Lilly, has assumed ... global services and chief financial officer, effective January 1. ... chief financial officer of the company and add responsibility for ...
Cached Medicine Technology:Pfizer Whistleblower Named Year's Most Influential Person In Business Ethics 2Lilly CFO Derica Rice Assumes Expanded Responsibilities, Promoted to Executive Vice President 2
(Date:7/24/2014)... 24, 2014 (HealthDay News) -- A new formulation of ... snorting or injecting the drug has been approved by ... ER and made by Purdue Pharma, the pill is ... drug that blocks the euphoric effects of oxycodone. The ... snorted, dissolved or injected, according to the FDA. ...
(Date:7/24/2014)... for the 4th Annual National Venous Interventional Summit ... VEINS is an established Venous Endovascular Interventional Strategies ... primary aim is to provide a "How To" ... are interested in advancing their knowledge and skills ... developing their own comprehensive venous interventional program. Topics ...
(Date:7/24/2014)... ACRIA & AMIDA CARE TO COHOST WHITE HOUSE ... Save the Dates: August 7th & August 8th* ... Dialogue for Life” forums this August, led by Douglas Brooks, ... National AIDS Policy (ONAP). This will be a wonderful opportunity ... AIDS organizations, consumers and advocates to advance the National HIV/AIDS ...
(Date:7/24/2014)... 24, 2014 National Analysts Worldwide, the ... it will operate globally under the name, NAXION ... woman-owned Employee Stock Ownership Plan (ESOP) organization led by ... Ph.D . The firm guides market strategy in ... , Said McDonald, “We wanted our name to ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 For the first time ... the United States. The Scottish singer first became a known musical ... Talent. Her first song on the show was “I Dreamed a ... has released five studio albums since her time on the reality ... perform in front of her American fans. The tour will kick ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... developed at UC Irvine that made paralyzed rats walk again ... in humans. , The U.S. Federal Drug Administration has approved ... by Hans Keirstead, co-director of the UCI Sue and Bill ... patients with acute spinal cord injury. , Geron Corp. of ...
... decreased 3.7 points to 45.7 in December, according to the latest ... Harris Interactive(R) on behalf of Spherion Corporation, indicates that workers are ... to find a new job. , , Results ... Sixty-six percent of workers believe ...
... San Antonio Officials with The University of Texas ... $1.2 million gift from the Robert J. Kleberg, Jr. ... to purchase a second generation aberration corrected electron microscope. ... nanotechnology researchers develop new cancer therapies and treatments that ...
... company, will it be a good deal or a bad deal? Fintan Walton, ... companies. , ... Oxford, UK (PRWEB) January 23, 2009 -- If Pfizer and Wyeth merge ... a bad deal? Fintan Walton, PhD, CEO of PharmaVentures, says, ‘This is potentially ...
... scientists will gather in Canberra this week for the ... a homecoming for the ANS which was formally created ... input from ANU. , A total of 535 presentations ... made by neuroscientists throughout the conference, revealing the latest ...
... Your Smile to Fit Your Life -CINCINNATI, Jan. 23 ... advanced innovation in teeth whitening technology: New Crest Whitestrips ... strip to users, teeth, allowing them to easily talk ... The secure fit comes off clean after whitening, ...
Cached Medicine News:Health News:UCI behind world's first embryonic stem cell study in humans 2Health News:Texas Employment Report: Employee Confidence Index Drops 2Health News:UTSA receives $1.2 million gift from Kleberg Foundation 2Health News:Pfizer - Wyeth: Good Deal – Bad Deal? 2Health News:The world's best brains descend on Canberra 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 2Health News:Crest Whitestrips Introduces a Revolutionary New Teeth Whitening Technology 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: